CinCor Pharma, Inc.
Index- P/E- EPS (ttm)-2.38 Insider Own0.10% Shs Outstand40.81M Perf Week4.41%
Market Cap1.13B Forward P/E- EPS next Y-2.55 Insider Trans- Shs Float38.84M Perf Month-21.90%
Income-88.10M PEG- EPS next Q-0.56 Inst Own94.70% Short Float / Ratio5.46% / 7.25 Perf Quarter-29.81%
Sales- P/S- EPS this Y-125.90% Inst Trans16.47% Short Interest2.12M Perf Half Y72.83%
Book/sh12.72 P/B2.09 EPS next Y-20.90% ROA-27.20% Target Price61.83 Perf Year-
Cash/sh12.31 P/C2.16 EPS next 5Y- ROE-33.00% 52W Range13.00 - 43.15 Perf YTD65.81%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.52% Beta-
Dividend %- Quick Ratio52.00 Sales past 5Y- Gross Margin- 52W Low104.08% ATR2.05
Employees19 Current Ratio52.00 Sales Q/Q- Oper. Margin- RSI (14)41.38 Volatility6.78% 8.23%
OptionableYes Debt/Eq0.00 EPS Q/Q10.70% Profit Margin- Rel Volume0.38 Prev Close25.63
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume292.43K Price26.53
Recom1.70 SMA20-7.79% SMA50-13.48% SMA2006.44% Volume111,372 Change3.51%
Oct-28-22Initiated Goldman Buy $67
Aug-22-22Initiated Piper Sandler Overweight $73
Feb-01-22Initiated Oppenheimer Outperform $30
Feb-01-22Initiated Morgan Stanley Overweight $27
Feb-01-22Initiated Jefferies Buy $30
Feb-01-22Initiated Evercore ISI Outperform
Nov-22-22 06:44PM
Nov-09-22 08:00AM
Nov-07-22 05:09PM
08:00AM Loading…
Nov-04-22 08:00AM
Nov-03-22 08:00AM
Oct-25-22 08:00AM
Oct-21-22 08:01AM
Oct-12-22 08:00AM
Oct-04-22 10:04AM
Sep-28-22 08:00AM
Sep-27-22 08:15AM
Sep-14-22 02:25PM
08:00AM Loading…
Aug-31-22 08:00AM
Aug-22-22 08:00AM
Aug-15-22 04:17PM
Aug-11-22 12:38AM
Aug-08-22 05:34PM
Jul-26-22 08:00AM
Jun-01-22 08:00AM
May-31-22 04:05PM
May-17-22 04:05PM
May-16-22 08:27AM
May-10-22 08:00AM
08:30AM Loading…
Apr-19-22 08:30AM
Apr-07-22 01:45PM
Mar-22-22 08:19AM
Mar-17-22 08:00AM
Mar-15-22 09:41AM
Mar-03-22 09:15AM
Jan-27-22 01:46PM
Jan-13-22 08:00AM
Jan-07-22 11:21AM
Jan-06-22 11:26PM
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sofinnova Partners SAS10% OwnerAug 15Buy30.00133,3333,999,9904,220,979Aug 17 04:19 PM
5AM Partners VI, LLC10% OwnerAug 15Buy30.00600,00018,000,0003,953,990Aug 17 08:01 PM
GENERAL ATLANTIC, L.P.10% OwnerAug 11Buy30.0083,0002,490,0004,209,470Aug 15 02:21 PM
GENERAL ATLANTIC GENPAR (BERMU10% OwnerAug 11Buy30.0083,0002,490,0004,209,470Aug 15 02:22 PM
Sofinnova Venture Partners X, 10% OwnerAug 11Buy30.00500,00015,000,0006,073,949Aug 15 03:46 PM
HEALY JAMESDirectorAug 11Buy30.00506,00015,180,0006,073,949Aug 15 03:45 PM
HEALY JAMESDirectorAug 05Option Exercise13.6029,411399,99029,411Aug 08 12:57 PM